



# Medmarc Risk Management Webinar Series

## Webinar Summary

### Changing Policies and Attitudes: Impacts on Medical Product Litigation

#### Presenters:

**Eric Alexander, Sara Klock, Juliet McBride, and Megan Mocho | Partners | Holland & Knight**

This on-demand webinar, recorded live on January 28, 2026, features a panel of experts from Holland & Knight who discussed the impacts of changing policies and attitudes on medical product litigation. The panel specializes in a variety of litigation areas, including product liability, life sciences, healthcare, FDA matters, and national security. The panel explored various regulatory changes affecting the life sciences industry, including FDA enforcement actions, CMS reimbursement initiatives, and healthcare enforcement practices. The discussion concluded with insights on False Claims Act implications and recent legal framework changes affecting FDA-regulated products, emphasizing the importance of documentation and compliance in navigating regulatory challenges.

---

### **Full On-demand Recording**

---

#### On-demand Chapters:

- 00:00 - Intro of Speakers; Partners of Holland & Knight
- 02:18 - Administrative Changes: FDA/HHS
- 08:39 - Administrative Changes: CMS
- 14:12 - Enforcement Changes
- 18:21 - Change Impacts
- 30:56 - Changing Attitudes: Agencies
- 38:05 - Changing Attitudes: Judges and Juries
- 44:18 - Policies and Attitudes Intersect
- 01:01:50 - Closing



**Eric Alexander** is a partner in Holland & Knight's Washington DC office, and he leads the firm's products liability life sciences litigation team.

[eric.alexander@hklaw.com](mailto:eric.alexander@hklaw.com)



**Megan Mocho** is a partner in the Tysons office specializing in white collar and false claims act investigations and defense. She co-leads the firm's National Security and Defense Industry group.

[megan.mocho@hklaw.com](mailto:megan.mocho@hklaw.com)



**Juliet McBride** is a partner in the firm's Houston office and is a member of the Healthcare Regulatory and Enforcement practice group focused on healthcare compliance and government investigations.

[juliet.mcbride@hklaw.com](mailto:juliet.mcbride@hklaw.com)



**Sara Klock** is a partner in the Washington DC office, and a member of the Public Policy & Regulation Group focused on food, agriculture, drug and device, digital health and life sciences.

[sara.klock@hklaw.com](mailto:sara.klock@hklaw.com)

## Additional Resources/References

- HHS OIG Work Plan ([Work Plan | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services](#))
- June 2025 CMS guidance doc on ASP ([ASP Restatement Policy Overview](#))
- CMS Pharmaceutical Manufacturer Enforcement Actions ([Pharmaceutical Manufacturer Enforcement Actions | CMS](#))
- [DOJ HHS False Claims Act Working Group](#)
- [Office of Public Affairs | The Department of Justice Creates New Civil Division Enforcement & Affirmative Litigation Branch | United States Department of Justice](#)
- [Office of Public Affairs | False Claims Act Settlements and Judgments Exceed \\$6.8B in Fiscal Year 2025 | United States Department of Justice \[justice.gov\]](#)
- [FY2025 FCA Stats \[justice.gov\]](#)
- [FY25 FCA Fact Sheet \[justice.gov\]](#)
- [U.S. Department of Justice Corporate Whistleblower Awards Pilot Program \[justice.gov\]](#)
- [Corporate Whistleblower Awards Pilot Program Intake Form \[justice.gov\]](#)
- [GAO-23-105210, THIRD-PARTY LITIGATION FINANCING: Market Characteristics, Data, and Trends \[gao.gov\]](#)



- [Why do so many Americans distrust science? | AAMC \[aamc.org\]](#)
- [Americans' Trust in Scientists and Views of Science Decline in 2023 | Pew Research Center \[pewresearch.org\]](#)
- [Americans' Trust in Scientists, Other Groups Declines in 2021 | Pew Research Center \[pewresearch.org\]](#)
- [How Americans see federal departments and agencies | Pew Research Center \[pewresearch.org\]](#)
- [Public Trust in Government: 1958-2025 | Pew Research Center \[pewresearch.org\]](#)
- [Trust In US Federal, State, And Local Public Health Agencies During COVID-19: Responses And Policy Implications | Health Affairs \[healthaffairs.org\]](#)
- [Generic Causation Experts Excluded In Sweeping Ruling From The Acetaminophen MDL | Drug & Device Law \[druganddevicelawblog.com\]](#)
- [Oral Argument for In Re: Acetaminophen - ASD-ADHD Products Liability Litigation – CourtListener.com \[courtlistener.com\]](#)
- [A Unanimous Supreme Court Sits Down A Hippo | Drug & Device Law \[druganddevicelawblog.com\]](#)